



**AID Life Science Holdings Limited**  
**(滙友生命科學控股有限公司)\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8088)**

**1ST QUARTERLY RESULTS**  
**FOR THE THREE MONTHS ENDED 31 MARCH 2020**

**CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)**

**GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.**

**Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.**

*Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this announcement misleading.*

\* For identification purposes only

## **ABOUT AID LIFE SCIENCE HOLDINGS LIMITED**

AID Life Science Holdings Limited (the “Company” and, together with its subsidiaries, the “Group”) is a strategic investment group listed on GEM (stock code: 8088).

The Group is principally engaged in the business of strategic investment.

## **MANAGEMENT DISCUSSION AND ANALYSIS**

During the three months under review, the Group continued to operate its strategic investment business. As part of the strategic investment business, the Group continued to monitor and strive to maximise the value of its strategic investments including, among others, (i) the development and operations of mobile/online games and mobile game distribution and publishing platform through its subsidiaries, Complete Star Limited and its subsidiary and Honestway Global Group Limited (“HGGL”) and its subsidiaries; (ii) in the movie distribution and artist management through its shareholding in China Creative Digital Entertainment Limited (stock code: 8078) (“China Creative“); (iii) in the United States of America for the businesses of robotics, pioneering autonomous mobility; (iv) in the People’s Republic of China in the development and operation of electric vehicle charging pile facility; and (v) the development in advanced personal molecular diagnostic services for cancer evaluation and cure through its investment in GeneSort.

## **IMPACT OF OUTBREAK OF CORONAVIRUS DISEASE 2019**

After the outbreak of Coronavirus Disease 2019 (“COVID-19 outbreak”) in early 2020, it had resulted in suspension of work in certain regions in the PRC. The epidemic has continued to spread and impacted global business and economic activities. A series of precautionary and control measures have been and continued to be implemented across the country/region. The Group will pay close attention to the development of the COVID-19 outbreak and evaluate its impact on the financial position and operating results of the Group. As at the date on which this set of consolidated financial statements were authorised for issue, the Group was not aware of any material adverse effects on the unaudited condensed consolidated financial information as a result of the COVID-19 outbreak.

## FINANCIAL REVIEW

Revenue in the first quarter of 2020 decreased to HK\$1.4 million from HK\$5.4 million in the first quarter of last year, while total operating expenses (being selling and distribution expenses and administrative and operating expenses) in the first quarter of 2020 decreased to HK\$10.2 million from HK\$20.1 million in the first quarter of last year.

Fair value loss on financial assets at fair value through profit or loss in the first quarter of 2020 decreased to HK\$1.8 million from HK\$2.9 million in the first quarter of last year.

Other net income in the first quarter of 2020 decreased to HK\$1.8 million from HK\$2.8 million in the first quarter of last year.

Finance costs in the first quarter of 2020 increased to HK\$4.2 million from HK\$3.6 million in the first quarter of last year, mainly represent the effective interest expense of the convertible bonds with principal amount of HK\$140 million.

As a result, the Group reported a loss attributable to owners of the Company in the first quarter of 2020 of HK\$14.5 million as compared to HK\$20.8 million in the first quarter of last year.

The Group will continue to monitor and strive to maximise the value of its various strategic investments globally. The Group also leveraged on its investment of GeneSort to develop and expand its foothold in the health-technology sector.

The Group will continue to (i) seize good opportunities from the potential fast growing specialised industry of health-technology; (ii) monitor and maximise the value of its investments; and (iii) seek for potential strategic investment and divestment opportunities with the objective to enhance the return to its shareholders.

## RESULTS

The board (the “Board”) of directors (the “Directors”) of the Company submit herewith the unaudited condensed consolidated results of the Group for the three months ended 31 March 2020, together with the comparative unaudited figures of the corresponding period in 2019, as follows:

### UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

		Unaudited Three months ended 31 March	
	Notes	2020 HK\$'000	2019 HK\$'000
<b>Revenue</b>	3	<b>1,394</b>	5,437
Cost of sales		<u>(992)</u>	<u>(4,660)</u>
<b>Gross profit</b>		<b>402</b>	777
Fair value loss on financial assets at fair value through profit or loss, net		<b>(1,809)</b>	(2,945)
Other net income	3	<b>1,799</b>	2,827
Selling and distribution expenses		–	(182)
Administrative and operating expenses		<u><b>(10,245)</b></u>	<u>(19,908)</u>
<b>Operation loss</b>		<b>(9,853)</b>	(19,431)
Finance costs		<b>(4,170)</b>	(3,627)
Share of results of an associate accounted for using equity method		<u><b>(850)</b></u>	<u>–</u>
<b>Loss before income tax</b>		<b>(14,873)</b>	(23,058)
Income tax credit	4	<u><b>390</b></u>	<u>567</u>
<b>Loss for the period</b>		<u><b>(14,483)</b></u>	<u>(22,491)</u>
<b>Attributable to:</b>			
Owners of the Company		<b>(14,452)</b>	(20,765)
Non-controlling interests		<u><b>(31)</b></u>	<u>(1,726)</u>
<b>Loss for the period</b>		<u><b>(14,483)</b></u>	<u>(22,491)</u>
<b>Loss per share attributable to owners of the Company</b>			
Basic (HK cents)	6(a)	<u><b>(2.65)</b></u>	<u>(3.84)</u>
Diluted (HK cents)	6(b)	<u><b>(2.65)</b></u>	<u>(3.84)</u>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OTHER  
COMPREHENSIVE INCOME**

	<b>Unaudited</b>	
	<b>Three months ended</b>	
	<b>31 March</b>	
	<b>2020</b>	<b>2019</b>
	<b>HK\$'000</b>	<b>HK\$'000</b>
<b>Loss for the period</b>	<b>(14,483)</b>	<b>(22,491)</b>
<b>Other comprehensive income:</b>		
<b>Items that may be reclassified to profit or loss:</b>		
Exchange differences on translation of foreign operations	<b>1,707</b>	60
Share of other comprehensive income of an associate	<b>14</b>	–
	<hr/>	<hr/>
Other comprehensive income for the period, net of tax	<b>1,721</b>	60
	<hr/>	<hr/>
<b>Total comprehensive loss for the period</b>	<b>(12,762)</b>	<b>(22,431)</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>Total comprehensive loss for the period</b>		
<b>Attributable to:</b>		
Owners of the Company	<b>(12,738)</b>	(21,367)
Non-controlling interests	<b>(24)</b>	(1,064)
	<hr/>	<hr/>
	<b>(12,762)</b>	<b>(22,431)</b>
	<hr/> <hr/>	<hr/> <hr/>

## **NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS**

### **1. GENERAL INFORMATION**

The Company was incorporated in the Cayman Islands on 21 February 2000 as an exempted company with limited liability under the Companies Law, Cap 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands and, its principal place of business is 22/F., New World Tower II, 18 Queen's Road Central, Central, Hong Kong. The Company's shares have been listed on GEM of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") since 17 April 2000. The Company and its subsidiaries are together referred to as the "Group" hereinafter.

The Company acts as the holding company of the Group. The Group is principally engaged in the business of strategic investment.

### **2. BASIS OF PREPARATION AND ACCOUNTING POLICIES**

The quarterly financial information has been prepared in accordance with all applicable International Financial Reporting Standards ("IFRSs") issued by the International Accounting Standards Board ("IASB") and disclosure requirements of the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited ("GEM Listing Rules").

The unaudited condensed consolidated financial information has been prepared under historical cost convention, except for certain financial assets and liabilities (including derivative instrument), which are measured at fair value.

It should be noted that accounting estimates and assumptions are used in preparation of the unaudited condensed consolidated financial information. Although these estimates are based on management's best knowledge and judgement of current events and actions, actual results may ultimately differ from those estimates. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the unaudited condensed consolidated financial information, are consistent with those set out in the Company's annual audited consolidated financial statements for the year ended 31 December 2019 ("2019 Annual Report").

This condensed consolidated financial information for the three months ended 31 March 2020 is unaudited, but has been reviewed by the audit committee of the Company.

This unaudited condensed consolidated financial information should be read in conjunction with the Company's 2019 Annual Report, which has been prepared in accordance with IFRSs. The principal accounting policies adopted to prepare this unaudited condensed consolidated financial information are consistent with those adopted to prepare to the Company's 2019 Annual Report.

The IASB has issued a number of new or revised IFRSs which are first effective for accounting period beginning on 1 January 2020, the adoption of these new or revised IFRSs has no material impact on how the Group's results and financial position for the current and prior periods have been prepared and presented.

The Group has not early adopted the new or revised IFRSs which have been issued but are not yet effective.

### **3. REVENUE AND OTHER NET INCOME**

Revenue represents the (i) sales of in-app purchases items, (ii) advertising income, (iii) real-time video streaming income and (iv) shared use facilities income.

Other net income mainly comprises interest income and net foreign exchange gains.

### **4. INCOME TAX CREDIT**

Under the two-tiered profits tax rates regime, the first HK\$2 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HK\$2 million will be taxed at 16.5%. Accordingly, the Hong Kong Profits Tax of the qualifying group entity is calculated at 8.25% on the first HK\$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK\$2 million. The profits of group entities not qualified for the two-tiered profits tax rates regime continue to be taxed at a flat rate of 16.5%.

Taxes on profits assessable elsewhere have been calculated at the rates prevailing in the relevant jurisdictions for the three months ended 31 March 2020 and 2019.

Deferred tax credit relating to the amortisation of intangible assets was recognised in profit or loss for the three months ended 31 March 2020 and 2019; while no recognition of potential deferred tax assets relating to tax losses of the Group has been made as the recoverability of the potential tax assets is uncertain.

## 5. MOVEMENTS IN RESERVES

	Share premium HK\$'000	Capital reduction reserve HK\$'000	Convertible bonds equity reserve HK\$'000	Capital reserve HK\$'000	Capital redemption reserve HK\$'000	Share-based compensation reserve HK\$'000	Remuneration share reserve HK\$'000	Foreign exchange reserve HK\$'000	Other reserve HK\$'000	Statutory surplus reserve HK\$'000	Accumulated losses HK\$'000	Total HK\$'000
At 1 January 2020 (Audited)	<u>768,129</u>	<u>702,955</u>	<u>1,921</u>	<u>2,112</u>	<u>601</u>	<u>57,159</u>	<u>9,028</u>	<u>(5,347)</u>	<u>(21,619)</u>	<u>5,163</u>	<u>(1,291,185)</u>	<u>228,917</u>
Loss for the period	-	-	-	-	-	-	-	-	-	-	(14,452)	(14,452)
Other comprehensive loss:												
Exchange differences on translation of foreign operations	-	-	-	-	-	-	-	1,700	-	-	-	1,700
Share of other comprehensive income of an associate	-	-	-	-	-	-	-	14	-	-	-	14
Total comprehensive loss for the period	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,714</u>	<u>-</u>	<u>-</u>	<u>(14,452)</u>	<u>(12,738)</u>
Remuneration shares issued for consultancy service	-	-	-	-	-	-	846	-	-	-	-	846
At 31 March 2020 (Unaudited)	<u>768,129</u>	<u>702,955</u>	<u>1,921</u>	<u>2,112</u>	<u>601</u>	<u>57,159</u>	<u>9,874</u>	<u>(3,633)</u>	<u>(21,619)</u>	<u>5,163</u>	<u>(1,305,637)</u>	<u>217,025</u>
At 1 January 2019 (Audited)	<u>762,257</u>	<u>702,955</u>	<u>1,921</u>	<u>2,112</u>	<u>601</u>	<u>57,159</u>	<u>10,400</u>	<u>(3,048)</u>	<u>(20,798)</u>	<u>5,163</u>	<u>(1,149,683)</u>	<u>369,039</u>
Loss for the period	-	-	-	-	-	-	-	-	-	-	(20,765)	(20,765)
Other comprehensive loss:												
Exchange differences on translation of foreign operations	-	-	-	-	-	-	-	(602)	-	-	-	(602)
Total comprehensive loss for the period	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(602)</u>	<u>-</u>	<u>-</u>	<u>(20,765)</u>	<u>(21,367)</u>
Remuneration shares issued for consultancy service	-	-	-	-	-	-	1,560	-	-	-	-	1,560
At 31 March 2019 (Unaudited)	<u>762,257</u>	<u>702,955</u>	<u>1,921</u>	<u>2,112</u>	<u>601</u>	<u>57,159</u>	<u>11,960</u>	<u>(3,650)</u>	<u>(20,798)</u>	<u>5,163</u>	<u>(1,170,448)</u>	<u>349,232</u>



## 6. LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

### (a) Basic

Basic loss per share is calculated by dividing loss attributable to owners of the Company by the weighted average number of ordinary shares in issue during the three months ended 31 March 2020 and 2019.

	<b>Unaudited</b>	
	<b>Three months ended</b>	
	<b>31 March</b>	
	<b>2020</b>	<b>2019</b>
<i>(HK\$'000)</i>		
Loss attributable to owners of the Company	<u>(14,452)</u>	<u>(20,765)</u>
<i>(Number of shares)</i>		
Weighted average number of ordinary shares	<u>545,107,005</u>	<u>540,232,005</u>
<i>(HK cents)</i>		
Basic loss per share	<u>(2.65)</u>	<u>(3.84)</u>

### (b) Diluted

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion/exercise of all potentially dilutive ordinary shares. The Company has three categories (2019: three categories) of potentially dilutive ordinary shares: remuneration shares, share options and convertible bonds. For the remuneration shares and share options, a calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares for the period) based on the monetary value of the subscription rights attached to outstanding remuneration shares and share options. The number of shares calculated as above is compared with the number of shares that would have been issued assuming the exercise of the share options. The convertible bonds were assumed to have been converted into ordinary shares, and the net loss has been adjusted to eliminate the interest expense, fair value change and gains/(losses) on early redemption less the tax effect.

For the three months ended 31 March 2020 and 2019, diluted loss per share is the same as the basic loss per share as the conversion/exercise of potential ordinary shares in relation to the outstanding remuneration shares, share options and convertible notes would have anti-dilutive effects to the basic loss per share.

## INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the three months ended 31 March 2020 (three months ended 31 March 2019: Nil).

## DISCLOSURE OF INTERESTS

### (A) DIRECTORS' INTERESTS

As at 31 March 2020, the interests of the Directors or any chief executive of the Company in the ordinary shares of the Company (the "Shares") and underlying Shares or any of its associated corporations as recorded in the register were:

#### (i) *Interests in the Shares*

Name of Directors	Personal interest	Corporate interest	Family interest	Aggregate long position in Shares	Approximate percentage of the issued share capital of the Company %
Mr. Wu King Shiu, Kelvin ("Mr. Wu") (Notes 1 and 2)	1,424,400	104,939,882	8,280,000	114,644,282	21.03
Ms. Chan Suet Ngan	19,850	–	–	19,850	0.003
Mr. Hu Kenneth (Note 3)	–	–	630,000	630,000	0.11
Ms. Qian Alexandra Gaochuan ("Ms. Qian") (Note 3)	630,000	–	–	630,000	0.11
Mr. Yuen Kwok On ("Mr. Yuen")	99,000	–	–	99,000	0.01

#### *Notes:*

1. Mr. Wu owns 1,424,400 Shares. Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited own 25,394,400 Shares, 45,454,545 Shares and 34,090,937 Shares, respectively. Mr. Wu is deemed to have interests in 25,394,400 Shares, 45,454,545 Shares and 34,090,937 Shares of which Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited were deemed to be interested by virtue of the Securities and Future Ordinance (the "SFO") since Mr. Wu through Billion Power Management Limited indirectly wholly owned AID Partners GP2, Ltd.. AID Partners GP2, Ltd. is the general partner of AID Partners Capital II, L.P. ("AID Cap II"). AID Cap II is interested in the entire issued share capital of Leader Fortune International Limited, which is interested in the entire issued share capital of Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited.
2. Billion Express Consultants Limited ("Billion Express") owns 8,280,000 Shares. The entire issued share capital of Billion Express is wholly owned by Ms. Li Mau, the spouse of Mr. Wu. Accordingly, Mr. Wu is deemed to be interested in the shares of the Company held by Billion Express.
3. Ms. Qian, the spouse of Mr. Hu Kenneth holds 630,000 Shares. Accordingly, Mr. Hu Kenneth is deemed to be interested in 630,000 Shares.

(ii) *Interests in the underlying Shares*

*Outstanding share options*

Name of Directors	Date of grant (dd/mm/yyyy)	Exercise price HK\$	Exercise period (Notes)	Balance as at 1 January 2020	Grant during the year	Exercised during the year	Cancelled/ lapsed during the year	Balance as at 31 March 2020
Mr. Wu	20/06/2014	3.20	(1)	1,344,200	-	-	-	1,344,200
	01/04/2016	4.94	(2)	3,500,000	-	-	-	3,500,000
	19/05/2017	1.56	(3)	450,000	-	-	-	450,000
				<u>5,294,200</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>5,294,200</u>
Ms. Chan Suet Ngan	01/04/2016	4.94	(2)	200,000	-	-	-	200,000
	19/05/2017	1.56	(3)	600,000	-	-	-	600,000
				<u>800,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>800,000</u>
Mr. Hu Kenneth	01/04/2016	4.94	(2)	200,000	-	-	-	200,000
	19/05/2017	1.56	(3)	1,400,000	-	-	-	1,400,000
				<u>1,600,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,600,000</u>
Ms. Qian	01/04/2016	4.94	(2)	200,000	-	-	-	200,000
	19/05/2017	1.56	(3)	1,400,000	-	-	-	1,400,000
				<u>1,600,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,600,000</u>
Mr. Yuen	01/04/2016	4.94	(2)	150,000	-	-	-	150,000
	19/05/2017	1.56	(3)	100,000	-	-	-	100,000
				<u>250,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>250,000</u>

*Notes:*

- (1) Exercisable from 20 June 2014 to 19 June 2024.
- (2) Divided into two tranches exercisable from 1 October 2016 and 1 April 2017, respectively to 31 March 2026.
- (3) Exercisable from 19 May 2017 to 18 May 2027.

**(iii) Short positions**

None of the Directors held short positions in the shares and underlying shares of the Company or any Associated Corporation.

Save as disclosed above, as at 31 March 2020, none of the Directors or chief executives of the Company had any interests and short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provision of the SFO), or which were recorded in the register required to be kept under section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules relating to securities transactions by Directors.

**(B) SUBSTANTIAL SHAREHOLDERS AND OTHER PERSONS**

As at 31 March 2020, the following persons, other than the Directors or chief executive of the Company, had interests or short positions in the shares and underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or is expected, directly or indirectly, to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of the Group.

**(i) Interests in the Shares and underlying Shares**

Name	Aggregate long position in Shares	Aggregate long position in underlying shares	Approximate percentage of the issued share capital of the Company %
<b>Substantial Shareholders</b>			
Mr. Wu (Notes 1 and 3)	114,644,282	5,294,200	22.00
Ms. Li Mau (Notes 1 and 3)	114,644,282	5,294,200	22.00
AID Cap II (Note 3)	104,939,882	–	19.25
AID Partners GP2, Ltd. (Note 3)	104,939,882	–	19.25
Hong Kong HNA Holding Group Co. Limited (Note 2)	66,141,232	21,538,461	16.08
Mr. David Tin	45,454,400	–	8.33
Billion Power Management Limited (Note 3)	104,939,882	–	19.25
Leader Fortune International Limited (Note 3)	104,939,882	–	19.25
Abundant Star Ventures Limited (Note 3)	45,454,545	–	8.33
Vantage Edge Limited (Note 3)	34,090,937	–	6.25
Mr. Wong Kwok Ho (“Mr. Wong”) (Notes 4 and 5)	32,558,200	14,250,000	8.58
Ms. Chau Mui (Notes 4 and 5)	32,558,200	14,250,000	8.58

*Notes:*

1. Mr. Wu, the Chairman and Non-Executive Director of the Company, owns 1,424,400 Shares and Billion Express owns 8,280,000 Shares. The entire issued share capital of Billion Express is wholly-owned by Ms. Li Mau, the spouse of Mr. Wu. Accordingly, Mr. Wu is deemed to be interested in the shares of the Company held by Billion Express. Mr. Wu is interested in 1,344,200 share options, 3,500,000 share options and 450,000 share options at an exercise price of HK\$3.20 per Share, HK\$4.94 per Share and HK\$1.56 per Share, respectively, to subscribe for Shares. Mr. Wu is deemed to have interest in 25,394,400 Shares, 45,454,545 Shares and 34,090,937 Shares as mentioned in note 3 below, respectively. Ms. Li Mau, as the spouse of Mr. Wu, is deemed to be interested in these Shares and underlying Shares for the purpose of the SFO.
2. Hong Kong HNA Holding Group Co. Limited is wholly-owned by HNA Financial Holdings International Co., Ltd. (“HNA Financial”). HNA Financial is wholly-owned by Beijing HNA Financial Holdings Co., Ltd. (“Beijing HNA”). Beijing HNA is owned as to 61.32% by HNA Investment Holding Co. Ltd. (“HNA Investment”) and owned as to 37.74% by Hainan HNA Holding Co., Ltd.. HNA Investment is owned as to 73.06% by HNA Holding Group Co., Ltd.. Hainan HNA Holding Co., Ltd. is owned as to 51.38% by HNA Holding Group Co., Ltd. and 21.61% by HNA Group Co., Ltd.. HNA Holding Group Co., Ltd. is wholly-owned by HNA Group Co., Ltd.. HNA Group Co., Ltd. is owned as to approximately 70% by Hainan Traffic Administration Holding Co., Ltd. (“Hainan Traffic”). Hainan Traffic is owned as to approximately 50% by Sheng Tang Development (Yangpu) Co., Limited (“Sheng Tang”). Sheng Tang is owned as to 35% by Tang Dynasty Development Co., Limited (“Tang Dynasty”) and 65% by Hainan Province Cihang Foundation. Tang Dynasty is owned as to approximately 98% by Pan-American Aviation Holding Company, which is in turn 100% beneficially owned by Cihang Sino-Western Cultural and Educational Exchange Foundation Limited.
3. Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited own 25,394,400 Shares, 45,454,545 Shares and 34,090,937 Shares. Mr. Wu is deemed to have interest in 25,394,400 Shares, 45,454,545 Shares and 34,090,937 Shares of which Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited are deemed to have interests by virtue of the SFO since Mr. Wu through Billion Power Management Limited indirectly wholly owned AID Partners GP2, Ltd.. AID Partners GP2, Ltd. is the general partner of AID Cap II. AID Cap II interested in the entire issued share capital of Leader Fortune International Limited, which is interested in the entire issued share capital of Hero Sign Limited, Abundant Star Ventures Limited and Vantage Edge Limited.
4. Mr. Wong owns 16,839,200 Shares and is interested in 4,500,000 share options at an exercises price of HK\$1.56 per Share to subscribe for Shares. Mr. Wong is deemed to be interested in 14,625,000 Shares and 9,750,000 underlying shares as mentioned in Note 5 below. Ms. Chau Mui, as the spouse of Mr. Wong, owns 1,094,000 Shares and is deemed to be interested in all Shares and underlying shares held by Mr. Wong.
5. Sky March Limited (“Sky March”) entered into a consulting service agreement with the Company dated 5 May 2017 (“Consulting Service Agreement”), pursuant to which the Company has issued 97,500,000 Shares (4,875,000 Shares adjusted upon the Share Consolidation), 97,500,000 Shares (4,875,000 Shares adjusted upon the Share Consolidation) and 4,875,000 Shares to Sky March on 25 May 2017, 28 May 2018 and 28 May 2019, respectively, and 9,750,000 Shares will be issued to Sky March in accordance with the terms and conditions of the Consulting Service Agreement. Mr. Wong is interest in these shares and underlying shares through his 100% interest in Sky March.

*(ii) Short positions*

No person held short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO.

Save as disclosed above, as at 31 March 2020, the Directors of the Company were not aware of any other person who had an interest or short position in the shares and underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO.

Save as disclosed above, as at 31 March 2020, no other person had interests which were recorded in the register required to be kept under section 336 of the SFO.

**(C) COMPETING INTERESTS**

So far as the Directors were aware, none of the other Directors or their respective associates were interested in any business which competes or is likely to compete, whether directly or indirectly, with the business of the Group.

**(D) SHARE OPTION SCHEMES**

The Company's share option scheme which was adopted on 27 March 2002 (the "2002 Share Option Scheme") was expired and a new share option scheme (the "2014 Share Option Scheme") was adopted by an ordinary resolution passed by the shareholders at the extraordinary general meeting of the Company on 15 April 2014 (the "Adoption Date"). The 2014 Share Option Scheme constitutes a share option scheme governed by Chapter 23 of the GEM Listing Rules and will remain in force for 10 years from the Adoption Date.

Upon the expiry of the 2002 Share Option Scheme, no further option can be offered thereunder but any options granted prior to such expiry but not yet exercised shall continue to be valid and exercisable.

The Company operates both the 2002 Share Option Scheme and the 2014 Share Option Scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operation. Pursuant to the 2014 Share Option Scheme, the Directors of the Company may grant options to eligible participants persons (as defined in the 2014 Share Option Scheme) to subscribe for shares in the Company subject to the terms and conditions stipulated therein.

## 2002 Share Option Scheme

The remaining share options granted under the 2002 Share Option Scheme are for other eligible participants and are exercisable as follows:

- (a) the first 30% of the options between the first and tenth anniversary of the date of grant;
- (b) the next 30% of the options between the second and tenth anniversary of the date of grant; and
- (c) the remaining options between the third and tenth anniversary of the date of grant.

The following table sets out information relating to the 2002 Share Option Scheme:

Date of grant (dd/mm/yyyy)	Grantees	Exercise period (dd/mm/yyyy)	Exercise price per share HK\$	Number of share options				Balance as at 31 March 2020
				Balance as at 1 January 2020	Granted during the period	Exercised during the period	Cancelled/Lapsed during the period	
07/10/2010	Former directors and former employees	07/10/2011 to 06/10/2020	4.00	118,528	-	-	-	118,528
16/03/2012	Former directors and former employees	16/03/2013 to 15/03/2022	4.00	267,129	-	-	-	267,129
14/05/2012	Former directors and former employees	14/05/2013 to 13/05/2022	3.80	292,968	-	-	-	292,968
				Total	678,625	-	-	678,625

No option was granted or exercised under the 2002 Share Option Scheme during the three months ended 31 March 2020.

The weighted average remaining contractual life of the options outstanding under the 2002 Share Option Scheme as at 31 March 2020 was approximately 1.77 years.

No share-based compensation expense was recognised under 2002 Share Option Scheme during the three months ended 31 March 2020 and 2019.

## 2014 Share Option Scheme

The following table sets out information relating to the 2014 Share Option Scheme:

Date of grant (dd/mm/yyyy)	Grantees	Exercise period (Notes)	Exercise price per share HK\$	Number of share options				Balance as at 31 March 2020
				Balance as at 1 January 2020	Granted during the period	Exercised during the period	Cancelled/ Lapsed during the period	
15/05/2014	Former directors	(1)	3.20	2,734,200	-	-	-	2,734,200
20/06/2014	Directors and former directors	(2)	3.20	1,623,262	-	-	-	1,623,262
01/04/2016	Directors and former directors	(3)	4.94	8,450,000	-	-	-	8,450,000
19/05/2017	Directors and former directors	(5)	1.56	5,300,000	-	-	-	5,300,000
				<u>18,107,462</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>18,107,462</u>
20/06/2014	Other eligible participants	(4)	3.20	1,770,138	-	-	-	1,770,138
01/04/2016	Other eligible participants	(3)	4.94	1,820,800	-	-	-	1,820,800
19/05/2017	Other eligible participants	(5)	1.56	11,809,600	-	-	-	11,809,600
				<u>15,400,538</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>15,400,538</u>
			Total	<u>33,508,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>33,508,000</u>

### Notes:

- (1) Exercisable from 15 May 2014 to 14 May 2024.
- (2) Exercisable from 20 June 2014 to 19 June 2024.
- (3) Divided into two tranches exercisable from 1 October 2016 and 1 April 2017, respectively to 31 March 2026.
- (4) Divided into two tranches exercisable from 20 June 2014 and 20 June 2015, respectively to 19 June 2024.
- (5) Exercisable from 19 May 2017 to 18 May 2027.



No option was granted or exercised under the 2014 Share Option Scheme during the three months ended 31 March 2020.

During the three months ended 31 March 2020, no option was lapsed upon resignation of other eligible participants.

The weighted average remaining contractual life of the options outstanding under the 2014 Share Option Scheme as at 31 March 2020 was approximately 6.25 years.

No share-based compensation expense was recognised under the 2014 Share Option Scheme in the condensed consolidated statement of profit or loss for the three months ended 31 March 2020 and 2019.

## **AUDIT COMMITTEE**

The Company established an Audit Committee on 31 March 2000 with the written terms of reference are available on the Company's website ([www.8088inc.com](http://www.8088inc.com)). The Audit Committee comprises three Independent Non-Executive Directors, Mr. Yuen Kwok On (Chairman), Mr. Matsumoto Hitoshi and Mr. Yau Chung Hang. The duties of the Audit Committee include: managing the relationship with the Group's external auditor, reviewing the financial information of the Company, and overseeing the Company's financial reporting process, risk management and internal control systems. The Audit Committee reports its work, findings and recommendations to the Board after each meeting.

The Audit Committee meets at least quarterly with the most recent meeting held on 8 May 2020. The unaudited condensed consolidated financial information of the Company for the three months ended 31 March 2020 has been reviewed by the Audit Committee.

## **PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES**

The Company has not redeemed any of its shares during the three months ended 31 March 2020 and 2019. Neither the Company, nor any of its subsidiaries, has purchased or sold any of the Company's listed securities during the three months ended 31 March 2020 and 2019.

By Order of the Board  
**AID Life Science Holdings Limited**  
**Wu King Shiu, Kelvin**  
*Chairman*

Hong Kong, 8 May 2020

*As at the date of this announcement, the Directors are:*

*Chairman and Non-Executive Director: Wu King Shiu, Kelvin*

*Executive Directors: Chan Suet Ngan, Hu Kenneth and  
Qian Alexandra Gaochuan*

*Independent Non-Executive Directors: Yuen Kwok On, Matsumoto Hitoshi and  
Yau Chung Hang*

*The English text for this announcement shall prevail over the Chinese text for the purpose of interpretation.*

*\* For identification purpose only*